Drugs / HG005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07063251 | Aug 2025 → Feb 2027 expected | Stargardt disease | HuidaGene Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HG005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07063251 ↗ |
| Action | Restore | “The goal of HG005 is to restore normal waste removal, protect retinal cells from further damage, and slow or stop vision loss.” NCT07063251 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “HG005 used two AAV vectors that work together in retinal cells to produce the full-length, functional ABCA4 protein.” NCT07063251 ↗ |
| Target | ABCA4 | “HG005 is an investigational gene therapy designed to deliver a healthy copy of the ABCA4 gene to the retina.” NCT07063251 ↗ |